Podium to Practice: ESMO® 2025 – GI: STELLAR-303

Podium to Practice: ESMO® 2025 – GI: STELLAR-303

Podium to Practice: ESMO® 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Scott Berry

Icon Chair Speaker

Speakers

Dr. Sharlene Gill

Dr. Marc Peeters

Studies / Trials Discussed

LBA30 – Zanzalintinib plus atezolizumab (zanza + atezo) vs regorafenib (rego) in patients (pts) with previously treated metastatic colorectal cancer (mCRC): Primary overall survival (OS) analysis from the randomized, open-label, phase 3 STELLAR-303 study

Studies/trials discussed:

LBA30 – Zanzalintinib plus atezolizumab (zanza + atezo) vs regorafenib (rego) in patients (pts) with previously treated metastatic colorectal cancer (mCRC): Primary overall survival (OS) analysis from the randomized, open-label, phase 3 STELLAR-303 study
Tagged